The Greater NY Node (GNYN) of the NIDA CTN, under the shared leadership of John Rotrosen and Edward Nunes, represents the 2010 merger of the New York and Long Island Nodes which have been part of the CTN since 2000 and 2001 respectively. This third competing renewal application builds on a strong and successful infrastructure for managing clinical trials and on a track record of innovation and successful implementation of addictions management in mainstream healthcare settings where the vast majority of SUD patients are seen. Our vision for the CTN of the future includes (1) a continued focus on integrating management of addiction in mainstream healthcare settings and management of medical conditions (e.g. HIV, HCV) in addictions settings, (2) a continued focus on leveraging health information technology which includes using EHRs to coordinate care and improve outcomes, (3) an evolving focus on studies to inform adaptive treatment strategies and on relatively low cost registry-based pragmatic comparative effectiveness studies, (4) a continued focus on stage 2 / phase 2 research where CTN resources can be efficiently used to develop new treatments, and (5) a platform on which focused- and population- level genetics-, clinical neuroscience-, epidemiology- and services- research and research training can be conducted. The GNYN has 15 years of CTN experience, and the expertise, resources and partners necessary to support this vision. The team has exceptional breadth and depth and an established track-record of collaboration both amongst researchers and with providers and institutions, particularly in the service of the proposed research agenda. The Node has complementary strengths in integration of addictions management in mainstream healthcare settings; health information technology, eHealth and mHealth; pharmacotherapy and vaccine development; behavioral therapy and combined medication-behavioral treatments; HIV, HCV and other infections; co-occurring psychiatric disorders; prevention, early intervention, pediatrics and adolescents; criminal justice populations; smoking and alcohol; genetics, clinical neuroscience and neuroimaging; clinical trials methodology; and dissemination, implementation and sustainability. Healthcare organizations include large public and private hospital-based systems (Bellevue Hospital Center, NY City Health and Hospitals Corp, Mount Sinai Health System, Einstein Montefiore Health System, VA NY Harbor Healthcare System and SUNY Upstate University Health System), all of which have addictions treatment services. Traditional specialty addictions programs include START, LESC, Odyssey House, Phoenix House and Narco Freedom, which provide a great range of addictions, medical and behavioral health services and which are keen to coordinate care with mainstream settings. We continue to engage policy-makers and dissemination experts, including the NY State OASAS, the NY City DOHMH, the NY City HHC, as well as the NeC-ATTC, and the National Center on Addiction and Substance Abuse (CASA), so that their input can inform the research agenda and foster adoption of innovation.
Addictions, including nicotine, drugs and alcohol, represent a major public health problem. Research is needed to translate new basic and therapeutic advances into effective and accessible treatment in our communities. The NIDA Clinical Trials Network and the Greater New York Node seek to fill this gap by engaging researchers, healthcare providers from primary care to specialty care, and policy-makers in research to improve addictions treatment nationally using science as the vehicle.
|McNeely, Jennifer; Kumar, Pritika C; Rieckmann, Traci et al. (2018) Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staff. Addict Sci Clin Pract 13:8|
|McCollister, Kathryn E; Leff, Jared A; Yang, Xuan et al. (2018) Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. Am J Manag Care 24:526-531|
|Hernandez, Yamilette; Meyers-Ohki, Sarah; Farkas, Sarah et al. (2018) How Massachusetts, Vermont, and New York Are Taking Action to Address the Opioid Epidemic. Am J Public Health 108:1621-1622|
|Venner, Kamilla L; Donovan, Dennis M; Campbell, Aimee N C et al. (2018) Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. Addict Behav 86:111-117|
|Zhu, Yuhui; Evans, Elizabeth A; Mooney, Larissa J et al. (2018) Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol 13:488-497|
|Lee, Joshua D; Nunes Jr, Edward V; Novo, Patricia et al. (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391:309-318|
|Campbell, Aimee N C; Barbosa-Leiker, Celestina; Hatch-Maillette, Mary et al. (2018) Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. Am J Addict 27:465-470|
|Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032|
|John, William S; Zhu, He; Mannelli, Paolo et al. (2018) Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients. Drug Alcohol Depend 187:79-87|
|Schwartz, R P; McNeely, J; Wu, L T et al. (2017) Identifying substance misuse in primary care: TAPS Tool compared to the WHO ASSIST. J Subst Abuse Treat 76:69-76|
Showing the most recent 10 out of 43 publications